WallStreetZenWallStreetZen

NASDAQ: NBIX
Neurocrine Biosciences Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Neurocrine Biosciences earnings were $705.5M for the trailing 12 months ending Jun 30, 2026, with 102.6% growth year over year. The latest NBIX earnings report on Jun 30, 2026 announced Q2 2026 earnings of $144.4M, down 27% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, NBIX reported annual earnings of $478.6M, with 40.2% growth.

NBIX past earnings growth

How has NBIX's earnings growth performed historically?

Company
102.59%
Industry
4.59%
Market
85.49%
NBIX's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
NBIX's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
NBIX's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

NBIX earnings history

Current Revenue
$3.4B
Current Earnings
$705.5M
Current Profit Margin
20.9%

NBIX Return on Equity

Current Company
21.1%
Current Industry
3.9%
Current Market
38.7%
NBIX's Return on Equity (21.1%)... subscribe to Premium to read more.
High Return on Equity Performance

NBIX Return on Assets

Current Company
14.7%
Current Industry
1.7%
NBIX is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when NBIX announces earnings.

NBIX Return on Capital Employed

Current Company
21.03%
Current Industry
4.5%
NBIX has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

NBIX vs Pharmaceutical Stocks

TickerEBITDAEarningsY/Y EarningsEPS
NBIX$1.01B$705.50M+12.51%$7.05
VTRS$2.47B-$296.50MN/A-$0.26
ELAN$731.00M-$242.00MN/A-$0.50
RDY$821.74M$442.67M+15.15%$0.53
ALKS$218.05M$66.12M-70.09%$0.40
View Top Pharmaceutical Stocks

Neurocrine Biosciences Earnings Reports & History FAQ

What were Neurocrine Biosciences's earnings last quarter?

On NBIX's earnings call on Jul 30, 2026, Neurocrine Biosciences (NASDAQ: NBIX) reported Q2 2026 earnings per share (EPS) of $1.43, up 31.19% year over year. Total NBIX earnings for the quarter were $144.40 million. In the same quarter last year, Neurocrine Biosciences's earnings per share (EPS) was $1.09.

If you're new to stock investing, here's how to buy Neurocrine Biosciences stock.

Is Neurocrine Biosciences profitable or losing money?

As of the last Neurocrine Biosciences earnings report, Neurocrine Biosciences is currently profitable. Neurocrine Biosciences's net profit (also called net income) for the twelve months ending Jun 30, 2026 was $705.50 million, a 102.56% increase year over year.

What was NBIX's earnings growth in the past year?

As of Neurocrine Biosciences's earnings date in Jul 30, 2026, Neurocrine Biosciences's earnings has grown 102.59% year over year. This is 98 percentage points higher than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 4.59%. NBIX earnings in the past year totalled $705.50 million.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.